How would the screening process apply to the large pharmaceutical companies in the portfolio?
Are the criteria different? Lester: The same strategies are used across various sectors. In the case of the large pharmaceutical companies, again it’s looking for companies with leading positions, gaining market share and you’re right it’s easier to manage. But they’re evaluated in a similar way. We value them using various methods such as discounted cash flow. Q: You have a staff of 20 people. Do they all research companies for the Life Sciences Fund? Lester: No. That is the entire research department here at Manning & Napier. We manage other mutual funds. We also have a big advisory business. We do a lot of the more traditional pension and 401(k) businesses. We do divide the analysts into different teams, based on sectors. In the life sciences area, we have six people. Healthcare is really important to us and we want to make sure that we’re staffed really well. Q: Do you rely upon outside opinions from physicians concerning the efficacy, for example, of promising drug candidates in l
Related Questions
- Aren Authorized Generics an effort by large pharmaceutical companies and their partners to circumvent the intent of the Hatch-Waxman Act which created the 180-day exclusivity period for the first generic drug approvals?
- With multi-national pharmaceutical companies (MNCs) looking more and more into large emerging markets as a promising source of growth, how important is Mexico in Roche’s expansion plans?
- What is Pharmaceutical Strategies’s screening process for candidates?
